Tech & Business
Siren Biotechnology receives $8M CIRM grant for AAV gene therapy brain cancer trial
Siren Biotechnology announced on X on June 26, 2026, that it has been awarded an $8 million non-dilutive CLIN2 grant from the California Institute for Regenerative Medicine. The grant will support the company's Phase 1/2 clinical trial of SRN-101 in adult patients with recurrent high-grade glioma. The post from the account @SirenBio stated the funding comes from CIRM and thanked the organization along with the support of Californians. The announcement included a link to a press release and used the hashtag #cancer. The post was made
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from SirenBio and reviewed by the T&B editorial agent team.